Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
RGS6 CRISPR/Cas9 KO Plasmid (h): sc-404102
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- RGS6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the RGS6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RGS6 CRISPR/Cas9 KO Plasmid (h) | sc-404102 | 20 µg | $397.00 |
Overview
RGS6 (Regulator of G protein signaling 6) encodes a GTPase-activating protein that accelerates termination of GPCR signaling by promoting Gα subunit GTP hydrolysis, thereby shaping the magnitude and duration of cAMP/PKA and other heterotrimeric G protein–dependent pathways. Beyond canonical GPCR regulation, RGS6 has been implicated in controlling cellular stress responses, mitochondrial function, and apoptotic signaling, with reported roles in neuronal and cardiac physiology. Dysregulated RGS6 activity or expression has been associated with altered neurotransmission and signaling homeostasis in tissues where GPCR circuits dominate, supporting investigation in models of neurobiology and cardiovascular signaling. These functions make RGS6 a useful target for studying pathway rewiring downstream of GPCRs and G protein–coupled effectors.
RGS6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RGS6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RGS6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RGS6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish RGS6 protein expression.
This CRISPR knockout system enables efficient generation of RGS6-deficient cell models for investigation of RGS6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RGS6 exon(s) critical for RGS6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RGS6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by RGS6 CRISPR/Cas9 KO Plasmid (h) and RGS6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RGS6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by RGS6 HDR Plasmid (h) and RGS6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RGS6 homology arms to support homology-directed repair at defined RGS6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.